Loading...
XNAS
AMRN
Market cap248mUSD
Oct 07, Last price  
12.02USD
1D
-0.41%
1Q
-20.50%
Jan 2017
-80.49%
Name

Amarin Corporation PLC

Chart & performance

D1W1MN
XNAS:AMRN chart
P/E
—
P/S
1.16
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.68%
Rev. gr., 5y
-19.04%
Revenues
214m
-6.55%
500,0007,365,0000000026,351,00054,202,00081,756,000130,084,000181,104,000229,214,000429,755,000614,060,000583,187,000369,193,000306,911,000228,614,000213,646,000
Net income
-39m
L-52.79%
-26,920,000-38,167,000-20,021,000-59,317,000-249,520,000-69,422,000-179,184,000-166,227,000-56,364,000-115,204,000-86,350,000-67,865,000-116,445,000-22,645,000-18,000,0007,729,000-105,803,000-59,112,000-82,183,000-38,798,000
CFO
7m
P
-22,909,000-26,279,000-26,392,000-28,112,000-33,870,000-39,439,000-122,303,000-190,336,000-72,309,000-84,748,000-71,815,000-32,837,000-94,703,000-9,366,000-21,746,000-66,529,072-179,980,8586,906,667-31,020,0006,743,722

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.

Key people

Odysseas Kostas
Non-Executive Independent Chairman of the Board · since 2023
Peter Fishman
Chief Financial Officer · since 2024
Stephen Ketchum
President - Research and Development, Executive Vice President, Chief Scientific Officer · since 2022
Jonathan Provoost
Executive Vice President, Chief Legal and Compliance Officer, Secretary · since 2023
Aaron Berg
President, Chief Executive Officer, Director · since 2024
Patrice Bonfiglio
Non-Executive Independent Director · since 2023
Paul Cohen
Non-Executive Independent Director · since 2023
Keith Horn
Non-Executive Independent Director · since 2023
Oliver O'Connor
Non-Executive Independent Director · since 2023
Louis Sterling
Non-Executive Independent Director · since 2023
Diane Sullivan
Non-Executive Independent Director · since 2023
Michael Torok
Non-Executive Independent Director · since 2025
URL
https://amarincorp.com/
IPO date
Apr 01, 1993
Employees
365
Domiciled in
IE
Incorporated in
GB
Headquarters & legal address
ONE NEW CHANGE
LONDON, LND EC4M 9AF
GB
Previous name
Ethical Holdings PLC
Previous name
Lockgen Limited

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT